Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.
Jan 13, 2021 1:13pm
Executive leaders at NeuroFlow include (l to r) Adam Pardes, COO and co-founder, Christopher Molaro, CEO and co-founder; and Julia Kastner, vice president of product. (NeuroFlow)
Behavioral health startup NeuroFlow secured a $20 million series B investment backed by managed care company Magellan Health.
NeuroFlow’s platform aggregates mental health data and builds comprehensive patient profiles, which care teams can use to identify patterns and treatment decisions. The company s technology facilitates healthcare management for patients in between traditional office-based visits.
The company s contracted user base has grown 10x times to over 330,000 and it works with more than 200 commercial health systems, payers, accountable care organizations, independent medical groups and federal agencies.